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Patients coinfected with hepatitis C virus (HCV) and Schistosoma mansoni show high incidence
of viral persistence and accelerated fibrosis. To determine whether immunological mechanisms
are responsible for this alteration in the natural history of HCV, the HCV-specific peripheral
CD4+ T cell responses and cytokines were analyzed in patients with chronic hepatitis C mono-
infection, S. mansoni monoinfection, or HCV and S. mansoni coinfection. An HCV-specific
CD4+ proliferative response to at least 1 HCV antigen was detected in 73.3% of patients infected
with HCV, compared with 8.6% of patients coinfected with HCV and S. mansoni. Stimulation
with HCV antigens produced a type 1 cytokine profile in patients infected with HCV alone,
compared with a type 2 predominance in patients coinfected with HCV and S. mansoni. In
contrast, there was no difference in response to schistosomal antigens in patients infected with
S. mansoni alone, compared with those coinfected with HCV and S. mansoni. These findings
suggest that the inability to generate an HCV-specific CD4+/Th1 T cell response plays a role in
the persistence and severity of HCV infection in patients with S. mansoni coinfection.
Hepatitis C virus (HCV) infection often is characterized by a
protracted clinical course with viral persistence, which leads to
liver cirrhosis and hepatocellular carcinoma in some individuals
[1–3]. Mechanisms underlying viral persistence and liver damage
in chronic HCV are not yet clarified, but a complex interplay of
virological and immunologic factors is implicated [4].
Virological factors that may be important are virus load,
genotype and quasi-species complexity [5–7]. The host immune
response probably plays a critical role in the control of both
HCV replication and liver injury [4]. HCV infection evokes
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CD4 HLA class II–restricted [8–10] and CD8 (cytotoxic T
lymphocytes) HLA class I–restricted T cell responses [11–13].
CD4 T lymphocytes have been shown to be crucial for re-
covering from acute HCV infection and for maintaining such
recovery, since the loss of HCV-specific CD4 responses corre-
lates with relapsing disease [14]. However, the role of CD4 cells
in the natural history of chronic HCV is not yet well established.
Schistosomiasis is a chronic helminth disease that infects
1200 million people worldwide [15]. Infection with Schistosoma
mansoni is endemic in Egypt, with a prevalence of 17.5%–42.9%
[16]. Morbidity in humans infected with S. mansoni results pri-
marily from the deposition of parasite ova in the portal areas
that induces a T cell–dependent granulomatous response, which
progresses to irreversible fibrosis and severe portal hypertension
in 160% of cases [17]. S. mansoni infection in mice is charac-
terized by a strong Th2-associated immune response that is
coupled with a defect in Th1–cell effector function [18–20].
Schistosomiasis and HCV coinfection is common in Egypt
[21–24] and other developing countries [25]. Patients coinfected
with HCV and schistosomiasis exhibit a unique clinical, viro-
logical, and histological pattern manifested by viral persistence
with high HCV RNA titers, as well as higher necro-
inflammatory and fibrosis scores in their liver biopsy samples
[23, 24]. However, no study to date has investigated the influ-
ence of S. mansoni on the HCV-specific cellular immune re-
sponse in this pattern of coinfection. We hypothesized that the
changes of the immune response that are induced by infection
with schistosomiasis might influence the HCV-specific immune
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Table 1. Demographic and baseline characteristics of patients in-
fected with hepatitis C virus (HCV) or Schistosoma mansoni alone and






S. mansoniHCV alone S. mansoni alone
No. 30 20 35
Male:female ratio 21:9 12:9 22:12
Age, years 42.6  8.1 38.5  3.6 44.2  6.7
Disease duration, years
HCV 7.4  4.1 6.5  3.9
S. mansoni 10.4  7.5 12.3  6.4
ALT, U/mL 53.5  31.1 23.5  5.7a 68.2  28.5a
AST, U/mL 58.5  27.3 28.5  5.7a 63.5  30.8a
RNA titer, 105 copies/mL 14.5  4.8b 28.8  8.7b
Histological grading scorec 5.9  2.8 1.5  0.1a 7.5  3.1a
Histological staging scorec 2.1  1.1d 1  0.1a 5.5  0.2a,d
NOTE. Data are , unless otherwise indicated. ALT, alanine ami-meanSD
notransferase; AST, aspartate aminotransferase.
a , patients infected with S. mansoni alone vs. coinfected patients.P ! .01
b , patients infected with HCV alone vs. coinfected patients.P ! .01
c Histological scoring is from Ishak et al. [29], including a necroinflammatory
grading score of 0–18 and a fibrosis staging score of 0–6. Liver biopsy specimens
also were assessed for morphologic features of schistosomiasis (0, no evidence for
schistosomiasis; 1, poor evidence for schistosomiasis; 2, suggestive of schistosomiasis;
3, strong evidence for schistosomiasis).
d , patients infected with HCV alone vs. coinfected patients.P ! .001
response, consequently altering the clinical and histological
course of HCV in this cohort of patients. Therefore, we inves-
tigated the specific CD4 proliferative response and cytokine
profile against HCV and S. mansoni antigens in patients coin-
fected with HCV and S. mansoni and compared them with
responses observed in patients infected with HCV or S. mansoni
alone. The spectrum of these responses was correlated to the
clinical and histological characteristics of these patients.
Patients and Methods
Patients. Eighty-five Egyptian patients (male:female ratio, 55:
30; mean age, years) with proven HCV infection and/or38.0 8.1
schistosomiasis were enrolled. Patients were matched for age, du-
ration of HCV infection, stage of liver disease at presentation, and
HCV genotype (genotype 4). Patients were categorized into 3 groups
(table 1). Group A included 30 patients infected with chronic HCV,
and inclusion criteria were as follows: seropositivity for antibody to
HCV (EIA 2; Abbott Laboratories), positive for HCV RNA by PCR,
HCV genotype 4, elevated aminotransferase levels for 6 months,
liver biopsy sample showing evidence of chronic hepatitis, and no
current or previous therapy with interferon (IFN) or ribavirin. Group
B included 20 patients infected with schistosomiasis alone, and in-
clusion criteria were as follows: history of schistosomiasis, detection
of S. mansoni ova in stool [26] or rectal biopsy sample, and sero-
positivity for schistosomal antibodies (indirect heamagglutination;
Femouz laboratories). Twelve patients had active schistosomiasis
(with viable S. mansoni ova in stool or rectal biopsy samples), whereas
8 had chronic infection (with a long history of schistosomiasis, re-
peated exposures, positive S. mansoni antibodies with either viable
or nonviable ova in stool or rectal biopsy samples). Group C included
35 patients with chronic HCV and schistosomiasis coinfection, which
were diagnosed by the above-mentioned criteria. All patients in group
C acquired S. mansoni infection before HCV, and all had viable S.
mansoni ova in stool or rectal biopsy samples. Ten healthy individ-
uals, who were matched for age and sex, served as control subjects.
The patients enrolled in the study had no serological markers
for the presence of hepatitis A, hepatitis B, hepatitis D, cytomega-
lovirus infection, Epstein-Barr virus infection, or other hepatic or
intestinal parasites. Autoimmune alcohol- or drug-induced liver
disease was ruled out. All patients were subjected to a physical
examination, and a clinical history was obtained. The duration of
the disease was defined as the interval between the probable time
of acquisition of HCV infection (determined by the date of intra-
venous antischistosomal therapy and/or blood transfusion) and/or
schistosomiasis (detected from the history of exposure and clinical
presentation) and enrollment.
HCV RNA was detected by reverse-transcription polymerase
chain reaction (RT-PCR; detection limit !2000 copies/mL), as de-
scribed elsewhere [27]. HCV RNA was quantitated by using the
Amplicor HCV Monitor kit (Roche Diagnostic Systems). HCV
genotype [28] was determined with the line-probe assay (INNO-
LiPA; Innogenetics).
Histological assessment. Liver biopsy samples were stained
with hematoxylin-eosin and a connective tissue stain (chromotrope
aniline blue). Liver biopsy samples were read in a blinded fashion
adopting the grading and scoring system proposed by Ishak et al.
[29], which includes grading of piecemeal necrosis, confluent ne-
crosis, apoptosis, focal inflammation, and portal inflammation with
a score of 0–18, and fibrosis was evaluated with a staging score
of 0–6. Moreover, biopsy samples were assessed for morphologic
features of schistosomiasis, such as S. mansoni ova, eosinophils,
granuloma, pigment, and fibrosis of pipe stem type. Evidence for
schistosomiasis was graded as follows: 0, no evidence for schis-
tosomiasis; 1, poor evidence for schistosomiasis; 2, suggestive of
schistosomiasis; and 3, strong evidence for schistosomiasis.
Antigens. Purified recombinant HCV proteins (core antigen, aa
2–120; nonstructural antigen 3 [NS3], aa 1192–1457; NS-4, aa
1569–1931; and NS5, aa 2054–2995), derived from the HCV-1 pro-
totype sequence, were purchased from Chiron Mimotopes. All an-
tigens were expressed as COOH-terminal fusion proteins with human
superoxide dismutase (SOD) in yeast. Yeast and SOD were used as
controls in each proliferation assay for nonspecific stimulation. Sol-
uble egg antigen (SEA) and soluble adult worm antigen protein
(SWAP) were a generous gift from Dr. K. Khalifa (Ain Shams Uni-
versity, Cairo) and were prepared as described elswhere [30, 31].
Proliferation assays. Peripheral blood mononuclear cells
(PBMC) from patients and control subjects were isolated imme-
diately after collection from fresh heparinized blood, using Ficoll-
Hypaque density gradient centrifugation, were washed with PBS,
and were resuspended in RPMI 1640 (Gibco) supplemented with
25 mM HEPES, 2 mM glutamine, 50 mg/mL gentamycin (Gibco),
and 10% human AB serum (complete medium). PBMC ( /52 10
mL) were cultured in 200 mL of complete medium/well in triplicates
in U-bottom 96-well plates (Costar) in the presence of HCV pro-
teins (10 mg/mL), schistosomal antigens (15–50 mg/mL), and phyto-
hemagglutinin (PHA; 1:200 final dilution; Murex Diagnostics) and
tetanus toxoid (Wyeth Laboratories) as positive controls, SOD as
974 Kamal et al. JID 2001;184 (15 October)
Figure 1. Comparison of overall CD4 cell response to hepatitis C virus (HCV) proteins (core antigen, nonstructural [NS] antigen 3, NS4,
and NS5), Schistosoma mansoni antigens (soluble egg antigen [SEA] and soluble adult worm antigen protein [SWAP]), and control antigen
(phytohemagglutinin [PHA]), expressed as the percentage of positive response in 3 patient groups (30 patients infected with chronic HCV alone,
20 patients infected with S. mansoni alone, and 35 patients coinfected with HCV and S. mansoni) and in 10 healthy control subjects. Although
73.3% of patients infected with HCV alone showed CD4 responses to at least 1 HCV antigen, only 8.3% of coinfected patients had a narrowly
focused response to only HCV core antigen, despite responding to S. mansoni and control antigen (*** , patients infected with HCVPp .0006
alone vs. coinfected patients, Wilcoxon rank sum test). HCV core antigen was the most frequently recognized HCV antigen, followed by NS3,
NS5, and NS4. Of 22 patients infected with HCV alone, 2 responded to all HCV proteins, 3 responded to 3 HCV antigens (core  2 NS antigens),
5 responded to 2 antigens (core  1 NS antigen), 8 responded to core antigen alone, and 4 responded to NS3 alone.
a negative control or no stimulation. Cultures were incubated at
37C in a humidified atmosphere with 5% CO2.
All proliferation assays were performed after 5 days of culture
with HCV antigens, schistosomal proteins, or controls. Prolifera-
tion assays were performed with the [3H]-thymidine incorporation
method. Cells were pulsed with 1 mCi [3H]-thymidine per well
(Amersham) for 18 h. Cells were harvested with an automatic cell
harvester (Filter Mate Universal Harvester; Packard) on glass filter
paper (Dunn), and [3H]-thymidine incorporation was determined
by liquid scintillation counting. Results were expressed as the
stimulation index (SI; counts per minute [cpm] incorporated in
response to antigen, divided by cpm incorporated in absence of
antigen). An SI of 3 was considered to be positive, which represents
3 SD above the mean SI of healthy control subjects (data not
shown). Since PBMC from coinfected patients showed poor or no
proliferation in response to HCV antigens, proliferation assays also
were performed in parallel, using the 5-bromo-2-uridine incorpo-
ration assay (ELISA detection kit; Boehringer Mannheim) for all
patients and control subjects, at different time points. The results
of both assays were comparable (data not shown).
CD4 and CD8 cell depletion. In some assays, proliferation
assays and cytokine release were done before and after CD4 and
CD8 depletion, to characterize the cell fractions that produced
the response. PBMC ( ) were suspended in 160 mL PBS610 10
supplemented with 0.5% bovine serum albumin and 2 mM EDTA.
Cells were stained with 40 mL paramagnetic microbeads conju-
gated to a monoclonal mouse anti–human CD8 antibody (Micro
Beads; Miltenyl Biotec) for 15 min at 4C. Magnetic separation
was performed by using a depletion column (Miltenyl Biotec),
which was placed in a magnetic field of a suitable separator. Fluo-
rescence-activated cell sorter analysis showed 195% CD4 after
CD8 depletion. Separated cells then were tested in a proliferation
assay for cytokine production.
Determination of cell phenotypes. Differentiation of CD4 and
CD8 lymphocytes was performed by direct fluorescence, using a
Coulter Epics II fluorescence-activated cell sorter with fluorescein
isothiocyanate–conjugated monoclonal antibodies specific for
CD4 and CD8 lymphocytes. T cell phenotype were determined
as follows: cells (1 ) cultured with the respective antigen or51 10
mitogen were incubated for 30 min at 4C with 2 mg/mL of the
monoclonal antibodies in different combinations for double stain-
ing (Leu-4 and anti-CD3; Leu-3a and anti-CD4; and Leu-2a and
anti-CD8; Becton Dickinson). Cells then were washed twice with
cold PBS and were analyzed on a FACstar flow cytometer.
Cytokine measurements. Serum cytokines were quantitated by
commercially available ELISA for IFN-g (BioSource Interna-
tional) and for interleukin (IL)–4, IL-10, and tumor necrosis factor
(TNF)–a (Boehringer Mannheim), according to the manufacturers’
instructions. After 48 h of incubation and antigen-specific stimu-
lation, 50 mL of cell-free supernatants were collected from all anti-
gen-stimulated and control wells and then were stored at 85C
until assayed for their cytokine content.
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Figure 2. Strength of CD4 proliferative response to the hepatitis C virus (HCV) proteins (core antigen, nonstructural [NS] antigen 3, NS4,
and NS5) and Schistosoma mansoni antigens (soluble egg antigen [SEA] and soluble adult worm antigen protein [SWAP]) relative to phytohem-
agglutinin (PHA). Results are expressed as the stimulation index (positive 13, which represents 3 SD above the mean stimulation index of normal
control subjects) of 3 patient groups (30 patients infected with chronic HCV alone, 20 patients infected with S. mansoni alone, and 35 patients
coinfected with HCV and S. mansoni) and 10 healthy control subjects. Patients infected with chronic HCV alone showed a more significant
response to core antigen, NS3, NS4, and NS5, compared with that of coinfected patients (*** , Student’s t test; , WilcoxonP ! .001 Pp .0006
rank sum test). There was no statistically significant difference in the strength of proliferative responses to S. mansoni antigens (SEA and SWAP)
between patients infected with S. mansoni alone and coinfected patients ( and , respectively). There was no significant differencePp .07 Pp .09
in the strength of proliferative response to PHA between patient groups and control subjects.
Figure 3. Relation of hepatitis C virus (HCV)–specific CD4 pro-
liferative response to HCV RNA titers (virus load). The mean CD4
proliferative response to HCV core antigen (stimulation index) is plot-
ted against the HCV RNA titers (copies 105/mL). The 2 parameters
show a positive relationship ( ; ).rp .49 P ! .05
HLA typing. DNA extraction and DRB1, DRB3, DRB4,
DRB5, DQA1, and DQB1 typing were performed by line-probe
assay (INNO-LiPA; Innogenetics), according to the manufacturer’s
instructions. In brief, genomic DNA was extracted from PBMC of
each patient and control subject, and biotin 5′ end–labeled primers
for DRB and DQB were used in PCR amplification. The PCR
products then were denatured before the addition of hybridization
buffer and were incubated in genotyping strips for 30 min at dif-
ferent temperatures, which then were washed.
Statistical analysis. Results were expressed as andmean SD
were analyzed by using paired and unpaired Student’s t test, x2
test, nonparametric Mann-Whitney U test, Wilcoxon rank sum test,
or Fisher’s exact test, as appropriate. Correlation between different
parameters was performed by using Pearson’s or Spearman’s rank
test. was considered to be significant. All statistical pro-P .05
cedures were performed by using SPSS software, version 10 for
Windows.
Results
The clinical, virological, and histological profile of all patients
is shown in table 1. Patients coinfected with HCV and S. man-
soni had higher HCV RNA titers and fibrosis scores, compared
with patients infected with either HCV or S. mansoni alone,
when matched for comparable disease duration and age. There
was no significant difference in inflammatory scores between
patients infected with HCV alone and patients coinfected with
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Figure 4. Cytokine production in response to hepatitis C virus (HCV) proteins (core antigen, nonstructural [NS] antigen 3, NS4, and NS5)
and Schistosoma mansoni antigens (soluble egg antigen [SEA] and soluble adult worm antigen protein [SWAP]) relative to phytohemagglutinin
(PHA). A, Interferon (IFN)–g; B, tumor necrosis factor (TNF)–a; C, interleukin (IL)–4; D, IL-10. Results are expressed as . Sixteenmean SD
patients infected with HCV alone showed significantly greater production of IFN-g and TNF-a in response to HCV antigens, which is consistent
with a type 1 CD4 T cell response, whereas 6 patients infected with HCV alone had IL-4 and IL-10 in addition to IFN-g detectable in supernatants,
which is consistent with a Th0 pattern. HCV stimulation produced IL-4 and IL-10 but no IFN-g in 3 coinfected patients who recognized HCV
core antigen and NS3 with a Th2 profile. A, 30 patients infected with chronic HCV; B, 20 patients infected with S. mansoni; C, 35 patients
coinfected with HCV and S. mansoni; N, 10 healthy control subjects.
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Figure 4. (Continued.)
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Figure 5. Serum cytokine levels of interferon (IFN)–g, tumor necrosis factor (TNF)–a, interleukin (IL)–4, and IL-10 in the 3 patient groups
and the control subject group: A, 30 patients infected with chronic hepatitis C virus (HCV); B, 20 patients infected with Schistosoma mansoni;
C, 35 patients coinfected with HCV and S. mansoni; N, 10 healthy control subjects. Results are expressed as . Boxes, median values;mean SD
vertical lines, ranges. ** ; *** between A and C; qqq between B and C.P ! .01 P ! .001 P ! .001
HCV and S. mansoni, although inflammatory scores were sig-
nificantly higher for patients infected with HCV alone and pa-
tients coinfected with HCV and S. mansoni, compared with
those for patients infected with S. mansoni alone. There was
no significant difference in HLA-DR phenotypes of the patients
in the 3 groups. DRB1 0101, 0401, 1101, 0701, and 1104 were
the most common HLA-DR molecules expressed in our patient
population (data not shown).
We first characterized the overall magnitude of CD4 response
in patients infected with HCV or S. mansoni alone and in patients
coinfected with HCV and S. mansoni by measuring the level of
PBMC proliferation in response to HCV proteins (core antigen,
NS3, NS4, and NS5) or S. mansoni proteins (SEA and SWAP)
relative to control antigens. The percentage of positive response
to each antigen is shown in figure 1, and the strength of response
to individual antigens is shown in figure 2. No patients infected
with HCV alone responded to schistosomal antigens, and no
patients infected with S. mansoni alone responded to any of the
HCV antigens. Overall, 22 (73.3%) of 30 patients infected with
HCV alone showed significant proliferative response to1 HCV
antigen (SI, 3.4–13.8). Of these 22 patients, 16 responded to core
antigen, 12 to NS3, 4 to NS5, and 3 to NS4. In striking contrast,
only 3 (8.6%) patients coinfected with HCV and S. mansoni
showed a weak, narrowly focused response to HCV core antigen
(SI, 3.2–4.8; , Wilcoxon rank sum test between patientsPp .0006
infected with HCV and patients coinfected with HCV and S.
mansoni), whereas 32 patients did not respond to any of the HCV
proteins (figure 2). Despite the very poor proliferative response
to HCV antigens, T cells from coinfected patients responded to
PHA (figure 2) and/or tetanus toxoid (data not shown) without
any statistically significant difference in the strength of prolif-
erative responses to non-HCV antigens, when compared with
responses in patients infected with HCV alone (figure 2). This
suggests that infection with S. mansoni specifically inhibited the
HCV-specific CD4 response in the coinfected patients. Compar-
ison of coinfected patients who responded to recombinant HCV
antigens with those who showed no response failed to show any
significant differences in age, disease duration, HLA-DR pheno-
types, or stage of liver disease. Moreover, this subset of coinfected
patients mounted a vigorous proliferative response against SEA
and SWAP that was not significantly different from the respones
in patients infected with S. mansoni alone (SEA, ; SWAP,Pp .07
; patients infected with S. mansoni alone and patientsPp .09
coinfected).
We then asked whether the vigor of the CD4 response could
be related directly to the virus load or the degree of liver dam-
age, since patients with advanced liver disease might have de-
pressed cellular immunity. The association between CD4 pro-
liferation assay results (SIs) against core antigen and HCV
RNA titer is plotted in figure 3. Patients showing positive HCV-
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Figure 6. A, Relation of tumor necrosis factor (TNF)–a to necroinflammatory scores. The 2 parameters show a positive relationship in patients
infected with hepatitis C virus alone ( ; ), whereas no such significant correlation could be detected in patients infected withrp .425 P ! .05
Schistosoma mansoni alone or in coinfected patients. B, Relation of interleukin (IL)–4 to fibrosis scores in all patients. The 2 parameters show a
positive relationship ( ; ). C, Relation of interferon (IFN)–g to fibrosis scores in all patients. The 2 parameters show a positiverp .63 P ! .05
relationship ( ; ).rp .415 P ! .05
specific responses had lower mean and median virus loads than
those who did not respond to HCV antigens ( ;rp.49 P !
). However, no statistically significant correlation was ob-.05
served between the proliferative CD4 response and the histo-
logical necroinflammatory scores (grading) or fibrosis scores
(data not shown). This suggests that the magnitude of the CD4
response is not a critical determinant of outcome in coinfection.
We then hypothesized that an alteration in the cytokine mi-
lieu exists with HCV and S. mansoni coinfection. Subsequently,
cytokine production in response to HCV, S. mansoni, and non-
specific stimulation was analyzed in patients and control sub-
jects. Figure 4 shows results of cytokine production in response
to HCV, S. mansoni, and mitogenic stimulation. Among 16
patients infected with HCV alone, HCV stimulation led to the
production of IFN-g and TNF-a but not IL-4 or IL-10, which
is consistent with a type 1 CD4 T cell response, whereas IL-4
and IL-10, in addition to IFN-g, were detectable in superna-
tants derived from 6 patients (Th0 profile), but no Th2 pattern
was found. In addition, all patients infected with HCV alone
produced IFN-g and TNF-a after mitogenic stimulation of
PBMC. On the other hand, HCV stimulation produced IL-4
and IL-10, but IFN-g (Th2 profile) was not produced in the 3
coinfected patients who recognized the HCV core antigen.
Stimulation with SEA and SWAP produced high levels of IL-
4 and IL-10 alone with a Th2 pattern in 16 of 20 patients
infected with S. mansoni alone and in 26 of 35 coinfected pa-
tients. IFN-g also was detected in supernatants from 4 of 20
patients infected with S. mansoni alone and from 9 of 35 coin-
fected patients. Therefore, only Th2 or Th0 patterns, but not
the Th1 profile, of cytokine production were observed in coin-
fected patients after HCV (in 3 responding coinfected patients),
S. mansoni, or nonspecific stimulation. In patients infected with
HCV alone, the amount of IFN-g produced after stimulation
with core antigen and NS3 was significantly higher than that
produced in the 3 coinfected patients who responded to the
HCV core antigen ( ).P ! .001
The levels of individual serum cytokines are shown in figure
5. Coinfected patients had high IL-4 and IL-10 levels, whereas
patients infected with HCV alone had higher IFN-g and TNF-
a levels. For all studied patients, there was no significant cor-
relation between TNF-a levels and the grading or staging
scores. However, a significant correlation did exist between
TNF-a and the necroinflammatory score when correlation was
restricted to patients infected with HCV alone ( ;rp .425 P !
; figure 6A). On the other hand, there was a significant direct.01
correlation between IL-4 levels and the fibrosis/cirrhosis score
(staging) and an inverse correlation between IFN-g levels and
the fibrosis/cirrhosis score (figure 6B and 6C). However, no
correlation was found between IFN-g, IL-4, or IL-10 and
necroinflammation (grading).
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Discussion
In previous studies, we and others reported that patients
coinfected with HCV and schistosomiasis have a more severe
clinical course, higher HCV RNA titers, higher incidence of
cirrhosis, hepatocellular carcinoma, poor response to IFN ther-
apy, and higher mortality rates due to liver-related causes, com-
pared with patients infected with HCV alone [23–25, 32]. Thus,
we investigated the possibility that this difference in clinical
outcome and course of HCV infection in coinfected patients
might be related to the alteration in HCV-specific CD4 T cell
response and cytokine profile caused by schistosomiasis. To test
this premise, which has not been studied before, we assessed
the HCV-specific CD4 T cell proliferative response and cyto-
kine profile in the largest cohort, to date, of patients coinfected
with HCV and S. mansoni versus patients infected with either
HCV or S. mansoni alone.
Our results showed that significant differences in HCV-spe-
cific CD4 T cell proliferative response and cytokine profile
could be detected between patients infected with HCV alone
and coinfected patients. In general, coinfected patients were
hyporesponsive to HCV antigen, despite their responsiveness
to control antigens. They responded to schistosomal antigens
and mitogen with a Th2/Th0 cytokine pattern, with elevated
IL-4 and IL-10 levels similar to those detected in patients in-
fected with S. mansoni alone, which has been described else-
where [18–20, 33]. On the other hand, 73.3% of patients infected
with chronic HCV alone were capable of mounting an HCV-
specific CD4 proliferative response with a Th1/Th0 cytokine
pattern, which is in accordance with the results of other studies
[8, 34–36]. Our results showed a higher HCV-specific CD4
proliferative response in patients infected with HCV alone,
compared with that reported elsewhere [8, 9, 10, 34]. This may
be attributed to the relatively shorter duration of HCV infection
in our patients.
Several lines of evidence suggest that the lack of HCV-specific
CD4 T cell recognition detected in the coinfected patients is due
to an influence of S. mansoni on the host immune system. It is
unlikely that the HCV genotype is responsible for nonrespon-
siveness, since in our study all patients infected with HCV alone
were infected with HCV genotype 4. Although proteins used in
this study were derived from an HCV genotype 1a isolate, a high
proportion of patients infected with HCV alone (73.3%), as well
as 3 (8.6%) coinfected patients, had responses to1 of the recom-
binant proteins used. Second, the lack of HCV CD4 response
in coinfected patients was not due to a decline in responses, since,
at entry, the patients were matched for age, duration of HCV
infection, and stage of liver disease. Lack of recognition of viral
antigens probably is not due to differences in HLA haplotypes,
since all patients infected with HCV, who were with or without
schistosomiasis, included in our study were from the same geo-
graphic area and displayed similar HLA-DR antigens. Therefore,
patients coinfected with S. mansoni had the potential to present
the immunodominant epitopes but were unable to mount a CD4
proliferative response.
In our study, the Th2 pattern was demonstrated to be domi-
nant in schistosomiasis, which is in agreement with previous
reports of human [20, 37] and murine models [18]. However,
the present study is the first to investigate the impact of the
Schistosoma-mediated predominance of a Th2 response and the
lack of a Th1 response during the course of HCV infection.
Although a predominant Th2 profile was shown to be beneficial
in polyparasitism, in which mice infected with S. mansoni are
capable of eliminating Trichuris muris infection more efficiently
than are noninfected mice [38], it is assumed to be harmful in
most viral infections. In our coinfected patients, HCV infection
probably was acquired after S. mansoni infection was estab-
lished, through parenteral antischistosomal therapy and/or
blood transfusions. Thus, in the first encounter of HCV with
the host immune system, it was confronted with a prevailing
Th2 pattern. One may speculate that this Th2 profile induced
by S. mansoni antagonized and down-regulated the antiviral
activities of Th1 cytokines, resulting in increased viral repli-
cation and more-aggressive progression to fibrosis. Imbalance
toward a Th2 profile at the time of acquisition of HCV infection
or during the acute stage of the disease may favor the faster
progression to chronicity in coinfected patients, which has been
described elsewhere [23–25]. This finding is further corrobo-
rated by Tsai et al. [39], since their analysis of the cytokine
profile of bulk cultures, as well as of CD4 T cell clones, from
patients infected with HCV revealed that viral clearance is more
likely in patients displaying a Th1 cytokine profile than in pa-
tients producing a Th2 cytokine profile.
In our study, coinfected patients had significantly high HCV
RNA titers and an inverse relationship between virus load and
CD4 T cell responses. This may be explained by the lack of
viral control due to defective HCV-specific CD4T cell response
or abrogation of the HCV-specific Th1 response, which is an-
tagonized by the S. mansoni–induced Th2 response. On the
other hand, the high initial virus load in these coinfected pa-
tients may cause immune exhaustion [40], thereby aggravating
HCV infection. This could not be confirmed in the current
study, since we did not assess the cytotoxic responses, which
we are currently assessing. However, Actor et al. [41] showed
that mice infected with vaccinia virus alone rapidly cleared the
virus, whereas viral clearance in animals coinfected with S.
mansoni was delayed in the liver by as much as 3 weeks and
in the spleen and lungs by several days. In another study [42],
BALB/c mice infected 7 weeks earlier with S. mansoni and
challenged with recombinant vaccinia virus vPE16, which ex-
presses the human immunodeficiency virus envelope protein
gp160, showed a marked delay in hepatic viral clearance, com-
pared with that in mice infected with vPE16 alone. This increase
in viral persistence was accompanied by reduced gp120-specific
Th1-associated cytokine responses, as well as by impaired cyto-
toxic T lymphocyte activity against targets expressing epitopes
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of the same antigen. These observations in the mouse model,
further supports our findings, which suggest that helminth in-
fection may influence immune responses to concurrent viral
infections.
S. mansoni causes liver pathology through an immune-me-
diated mechanism, rather than through direct hepatic injury
[33]. S. mansoni ova are trapped in the liver, evoking a highly
skewed Th2 immune response profile with granuloma forma-
tion that progresses to periportal fibrosis. However, the ultra-
structure and function of hepatocytes are minimally affected.
Our study, as well as previous reports [23–25], showed that
patients infected with schistosomiasis alone had very low in-
flammatory scores (!2), with no piecemeal necrosis. The high
fibrosis scores of patients with concomitant infection may be
immunologically mediated with predominance or up-regulation
of the collagen-inducing cytokine IL-4 and the down-regulation
of the collagen-suppressing cytokine IFN-g, as was detected in
our study and in other studies of schistosomiasis in mice [43,
44] or in humans [37]. However, it is important to consider that
our study focused on the peripheral blood compartment, which
may reflect only immune events that occur in the liver, because
of compartmentalization of immune responses [9, 45].
In conclusion, our data show that patients coinfected with
chronic HCV and schistosomiasis fail to mount significant
HCV-specific CD4 T cell responses and show alteration in the
cytokine milieu, along with more-severe liver disease. This also
may have important implications for treatment, since it would
imply that down-regulation of immune responses, at least early
in disease, may have an adverse impact on disease progression.
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